皮质类固醇治疗糖尿病性黄斑水肿的药理学
本综述聚焦于治疗糖尿病性黄斑水肿的皮质类固醇的基础科学与药理学,阐述了临床可用皮质类固醇在效力、药代动力学、基因激活及安全性和疗效方面的差异,并指出理解这些差异有助于药物选择及未来新型皮质类固醇的发现。
要点
- 临床可用皮质类固醇的效力、药代动力学及在不同靶组织激活的基因均存在差异。
- 这些差异与不同的疗效、药代动力学和安全性特征相关。
- 理解上述差异对选择皮质类固醇治疗糖尿病性黄斑水肿很重要。
核心结论
- 对皮质类固醇基础科学认识的进展可解释这些药物在疗效和安全性方面的临床差异,并应有助于未来发现治疗糖尿病性黄斑水肿的新型皮质类固醇。
研究设计与样本
- 综述,检索并总结用于治疗糖尿病性黄斑水肿的皮质类固醇的基础科学与药理学。
主要发现
- 临床可用皮质类固醇不仅效力和药代动力学不同,且在不同靶组织中激活不同基因。
- 上述差异与不同的疗效、药代动力学和安全性特征相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Corticosteroids remain the mainstay of treatment for inflammatory diseases almost 80 years after their first clinical use. Topical ophthalmic formulations of corticosteroids have been available to treat disease of the anterior segment of the eye, but the approval of corticosteroids to treat vitreoretinal diseases, including vein occlusion, diabetic macular edema, and uveitis, has occurred only recently. Although most diseases respond to corticosteroid therapy, some patients are resistant to this therapy and side effects, including cataract and elevated intraocular pressure, can limit their use. The purpose of this review is to detail the basic science of corticosteroids focusing on differences in potency, drug delivery, pharmacokinetics, and gene activation, and how these differences affect safety and efficacy in the treatment of diabetic macular edema. METHODS: A review was conducted of basic science and pharmacology of the corticosteroids used to treat diabetic macular edema. RESULTS: Clinically available corticosteroids not only have differing potency and pharmacokinetics, but also activate different genes in different target tissues. These differences are associated with distinct efficacy, pharmacokinetic, and safety profiles. It is important to understand these differences in selecting corticosteroids to treat diabetic macular edema. CONCLUSIONS: Recent advances in our understanding of the basic science of corticosteroids can explain clinical differences in these agents regarding efficacy and safety. Importantly, this understanding should allow the future discovery of additional novel corticosteroids to treat diabetic macular edema.
引用
- Whitcup SM, Cidlowski JA, Csaky KG, et al. Pharmacology of Corticosteroids for Diabetic Macular Edema. Invest Ophthalmol Vis Sci. 2018. PMID: 29297055. doi:10.1167/iovs.17-22259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。